Descrizione
Summary diagram of melatonin's dual mechanism in prostate cancer: reducing intracrine androgen biosynthesis through both lipid/cholesterol depletion and direct inhibition of androgen synthesis enzymes.
Figure 25
DiagramSource Paper
Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.Cite This Figure
![Figure 25: Summary diagram of melatonin's dual mechanism in prostate cancer: reducing intracrine androgen biosynthesis through both lipid/cholesterol depletion and direct inhibition of androgen synthesis enzymes.]() > Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)
<figure> <img src="" alt="Summary diagram of melatonin's dual mechanism in prostate cancer: reducing intracrine androgen biosynthesis through both lipid/cholesterol depletion and direct inhibition of androgen synthesis enzymes." /> <figcaption>Figure 25. Summary diagram of melatonin's dual mechanism in prostate cancer: reducing intracrine androgen biosynthesis through both lipid/cholesterol depletion and direct inhibition of androgen synthesis enzymes.<br> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption> </figure>